C-HZUXMDI Therapeutics
PAI-1 inhibition, anti-fibrotic therapeutics
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-HZUX
C-HZUXC-HZUXPAI-1 inhibition, anti-fibrotic therapeutics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
MDI Therapeutics PAI-1 inhibition, anti-fibrotic therapeutics
MDI Therapeutics is a pharmaceutical company developing novel therapies for fibrosis and fibroproliferative diseases. The company was founded on key enabling technologies developed at the University of Michigan. Its lead program is a first-in-class orally available inhibitor of plasminogen activator inhibitor-1.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
MDI Therapeutics — Translational · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: phase 1. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic